Senescence-Related lncRNA Signature Predicts Prognosis, Response to Immunotherapy and Chemotherapy in Skin Cutaneous Melanoma

Kefan Lin; Yingtong Zhou; Yanling Lin; Yuanyuan Feng; Yuting Chen; Longmei Cai

doi:10.3390/biom13040661

Senescence-Related lncRNA Signature Predicts Prognosis, Response to Immunotherapy and Chemotherapy in Skin Cutaneous Melanoma

Biomolecules. 2023 Apr 9;13(4):661. doi: 10.3390/biom13040661.

Authors

Kefan Lin¹, Yingtong Zhou¹, Yanling Lin¹, Yuanyuan Feng¹, Yuting Chen², Longmei Cai¹

Affiliations

¹ Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
² First Clinical Medical College, Southern Medical University, Guangzhou 510515, China.

Abstract

Skin cutaneous melanoma (SKCM) is a highly malignant and aggressive cancer. Previous studies have shown that cellular senescence is a promising therapeutic strategy to limit melanoma cell progression. However, models to predict the prognosis of melanoma based on senescence-related lncRNAs and the efficacy of immune checkpoint therapy remain undefined. In this study, we developed a predictive signature consisting of four senescence-related lncRNAs (AC009495.2, U62317.1, AATBC, MIR205HG), and we then classified patients into high- and low-risk groups. GSEA (Gene set enrichment analysis) showed different activation of immune-related pathways in two groups. In addition, there were significant differences between the scores of tumor immune microenvironment, tumor burden mutation, immune checkpoint expression, and chemotherapeutic drug sensitivity between the two groups of patients. It provides new insights to guide more personalized treatment for patients with SKCM.

Keywords: chemotherapy drugs; immunotherapy; lncRNA; melanoma; prognostic signature; senescence; tumor burden mutation; tumor immune microenvironment.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Humans
Immunotherapy
Melanoma* / drug therapy
Melanoma* / genetics
Melanoma, Cutaneous Malignant
RNA, Long Noncoding* / genetics
Skin Neoplasms* / drug therapy
Skin Neoplasms* / genetics
Tumor Microenvironment / genetics

Substances

RNA, Long Noncoding

Grants and funding

This research was funded by Key projects funded by the President of Nanfang Hospital of Southern Medical University (Grant numbers 2021A006). Author Longmei Cai has received research support from Nanfang Hospital.